Retatrutide, a novel dual stimulator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) binding site , is demonstrating promising data in early patient trials . Current https://pr8bookmarks.com/story21481118/retatrutide-emerging-studies-and-potential-medical-roles